NOXXON Pharma AG

NOXXON Pharma AG (NOXXON) is a biopharmaceutical company. It is engaged in the development of pharmaceutical products based on proprietary Spiegelmer Technology. The company develops Spiegelmers (L-aptamers) for the treatment of inflammatory diseases, hematological conditions, and other indications. It focuses on the therapeutic areas of metabolic disorders like diabetes, inflammatory diseases, cancer, anemia of inflammation and autologous stem cell transplantation. Its pipeline products include NOX-E36 (MCP-1) for lupus nephritis/diabetic nephropathy, NOX-A12 (SDF-1) for analogues stem cell transplantation, NOX-H94 (Hepicidin) for Anemia of Inflammation. The company is headquartered in Berlin, Germany.

Recently, the company signed a licensing and drug discovery agreement with Eli Lilly, Pfizer, and Roche companies regarding the discovery and development of Spiegelmers for the treatment of migraine.

Street: 
Max-Dohrn-Strasse 8-10
City: 
Berlin
Postcode: 
10589
Federal State : 
Germany
WebSite: 
http://www.noxxon.net
Fax: 
49-30-726247225

Company Index Score

Current Index Score Historical Index Score
  • NOXXON Pharma AG currently scores 50 % in the index.
  • NOXXON Pharma AG is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • NOXXON Pharma AG is currently ranked 1 out of 4535 companies. This is in the top 0.022 % percent of Pharmaceutical companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets